肺動脈性肺高血圧症の市場規模、シェア、成長分析：薬剤クラス別、タイプ別、投与経路別、流通チャネル別、地域別 - 産業予測 2025～2032年

肺動脈性肺高血圧症の世界市場規模は2023年に77億9,000万米ドルとなり、予測期間（2025～2032年）のCAGRは5.3%で、2024年の82億米ドルから2032年には124億米ドルに成長する見通しです。

肺動脈性肺高血圧症（PAH）市場は、罹患率の増加、希少疾病用医薬品開発に対する政府の支援強化、高齢者人口の増加など、いくつかの主な要因によって成長が見込まれています。システマティック・レビューによると、PAHの有病率は10万人当たり0.4％から1.4％であり、高血圧に罹患している30～79歳の人口は世界で推定12億8,000万人に上り、主に低・中所得国で罹患しています。WHOは、2010年から2030年までに高血圧有病率を33％減少させるという重要な目標を設定し、この分野におけるさらなる調査と治療法の必要性を強調しています。これらの知見を総合すると、PAH治療の進歩が期待されます。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次データと一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析

肺動脈性肺高血圧症市場規模：薬剤クラス別

• 市場概要
• エンドセリン受容体拮抗薬（ERA）
• PDE-5阻害剤
• プロスタサイクリンおよびプロスタサイクリン類似体
• SGC刺激装置

肺動脈性肺高血圧症市場規模：タイプ別

• 市場概要
• ブランド
• ジェネリック

肺動脈性肺高血圧症市場規模：投与経路別

• 市場概要
• オーラル
• 静脈内/皮下
• 吸入

肺動脈性肺高血圧症市場規模：流通チャネル別

• 市場概要
• 病院
• 小売薬局
• オンライン薬局

肺動脈性肺高血圧症市場規模

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 市場の最近の動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 会社概要
  • 製品ポートフォリオ分析
  • セグメント別シェア分析
  • 収益の前年比比較（2022～2024年）

主要企業プロファイル

• United Therapeutics Corporation（United States）
• Bayer AG（Germany）
• GlaxoSmithKline plc（United Kingdom）
• Gilead Sciences, Inc.（United States）
• Novartis International AG（Switzerland）
• Pfizer Inc.（United States）
• Merck & Co., Inc.（United States）
• Bristol-Myers Squibb Company（United States）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Viatris Inc.（United States）
• Sun Pharmaceutical Industries Ltd.（India）
• Alembic Pharmaceuticals Ltd.（India）
• Aerami Therapeutics Holdings Inc.（United States）
• Asklepion Pharmaceuticals LLC（United States）
• Keros Therapeutics（United States）
• Liquidia Corporation（United States）
• Ferrer（Spain）
• Gossamer Bio（United States）

結論と推奨事項

Global Pulmonary Arterial Hypertension Market size was valued at USD 7.79 billion in 2023 and is poised to grow from USD 8.2 billion in 2024 to USD 12.4 billion by 2032, growing at a CAGR of 5.3% during the forecast period (2025-2032).

The pulmonary arterial hypertension (PAH) market is poised for growth due to several key factors, including the increasing incidence of the disease, enhanced government support for orphan drug development, and a growing elderly population. A systematic review highlighted the prevalence of PAH, indicating it affects between 0.4% and 1.4% of individuals per 100,000, with an estimated 1.28 billion people aged 30-79 globally affected by hypertension, predominantly in low- and middle-income countries. The WHO has set significant targets to reduce hypertension prevalence by 33% from 2010 to 2030, emphasizing the need for further research and treatment options in this area. Collectively, these insights set a promising stage for advancements in the PAH treatment landscape.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Pulmonary Arterial Hypertension market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Pulmonary Arterial Hypertension Market Segmental Analysis

Global Pulmonary Arterial Hypertension Market is segmented by Drug Class, Type, Route of Administration, Distribution Channel and region. Based on Drug Class, the market is segmented into Endothelin Receptor Antagonists (ERAs), PDE-5 Inhibitors, Prostacyclin and Prostacyclin Analogs and SGC Stimulators. Based on Type, the market is segmented into Branded and Generics. Based on Route of Administration, the market is segmented into Oral, Intravenous/ subcutaneous and Inhalational. Based on Distribution Channel, the market is segmented into Hospitals, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Pulmonary Arterial Hypertension Market

The global pulmonary arterial hypertension (PAH) market is experiencing significant growth due to the increasing prevalence of this rare yet progressive condition, which is characterized by elevated blood pressure in the arteries leading to the lungs. Factors contributing to this rise include aging populations, a growing incidence of risk factors such as obesity, and advancements in diagnostic techniques. Consequently, there is a heightened demand for effective PAH treatments. Furthermore, the development of innovative therapies, including prostacyclin analogues, endothelin receptor antagonists, and phosphodiesterase inhibitors, has bolstered market growth due to their improved efficacy and safety profiles, ultimately driving greater patient interest and need for these medications.

Restraints in the Global Pulmonary Arterial Hypertension Market

The global market for pulmonary arterial hypertension (PAH) faces certain constraints due to the limited pool of patients affected by this rare disease. Unlike more prevalent chronic conditions, PAH has a low incidence rate, which can significantly impact the commercial potential of therapeutic drugs designed for treatment and may deter investment in research and development. Additionally, diagnosing PAH requires a series of complex tests, including echocardiography, right heart catheterization, and pulmonary function assessments. Furthermore, symptoms such as fatigue and shortness of breath are often vague and can be misattributed to other health issues, resulting in delayed or incorrect diagnoses that hinder patient access to appropriate care.

Market Trends of the Global Pulmonary Arterial Hypertension Market

The Global Pulmonary Arterial Hypertension (PAH) market is witnessing a significant shift towards personalized medicine, driven by technological advancements and a deeper comprehension of the disease's genetic underpinnings. Pharmaceutical companies are heavily investing in research and development initiatives aimed at discovering biomarkers that can enhance the predictability of disease progression and treatment efficacy. This trend is fostering the creation of tailored therapies that specifically address varying genetic mutations associated with PAH, thereby improving patient outcomes. As a result, the market is poised for robust growth, characterized by innovation, a focus on individualized treatment regimens, and a commitment to precision healthcare solutions.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Pulmonary Arterial Hypertension Market Size by Drug Class & CAGR (2025-2032)

• Market Overview
• Endothelin Receptor Antagonists (ERAs)
• PDE-5 Inhibitors
• Prostacyclin and Prostacyclin Analogs
• SGC Stimulators

Global Pulmonary Arterial Hypertension Market Size by Type & CAGR (2025-2032)

• Market Overview
• Branded
• Generics

Global Pulmonary Arterial Hypertension Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Intravenous/ subcutaneous
• Inhalational

Global Pulmonary Arterial Hypertension Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospitals
• Retail Pharmacies
• Online Pharmacies

Global Pulmonary Arterial Hypertension Market Size & CAGR (2025-2032)

• North America (Drug Class, Type, Route of Administration, Distribution Channel)
  • US
  • Canada
• Europe (Drug Class, Type, Route of Administration, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Class, Type, Route of Administration, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Class, Type, Route of Administration, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Class, Type, Route of Administration, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• United Therapeutics Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis International AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alembic Pharmaceuticals Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aerami Therapeutics Holdings Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Asklepion Pharmaceuticals LLC (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Keros Therapeutics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Liquidia Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ferrer (Spain)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gossamer Bio (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations